Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT).

Connor, Philip; Sánchez van Kammen, Mayte; Lensing, Anthonie W A; Chalmers, Elizabeth; Kállay, Krisztián; Hege, Kerry; Simioni, Paolo; Biss, Tina; Bajolle, Fanny; Bonnet, Damien; Grunt, Sebastian; Kumar, Riten; Lvova, Olga; Bhat, Rukhmi; Van Damme, An; Palumbo, Joseph; Santamaria, Amparo; Saracco, Paola; Payne, Jeanette; Baird, Susan; ... (2020). Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). Blood advances, 4(24), pp. 6250-6258. American Society of Hematology 10.1182/bloodadvances.2020003244

[img] Text
advancesadv2020003244.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (855kB) | Request a copy

Anticoagulant treatment of pediatric cerebral venous thrombosis has not been evaluated in randomized trials. We evaluated the safety and efficacy of rivaroxaban and standard anticoagulants in the predefined subgroup of children with cerebral venous thrombosis (CVT) who participated in the EINSTEIN-Jr trial. Children with CVT were randomized (2:1), after initial heparinization, to treatment with rivaroxaban or standard anticoagulants (continued on heparin or switched to vitamin K antagonist). The main treatment period was 3 months. The primary efficacy outcome, symptomatic recurrent venous thromboembolism (VTE), and principal safety outcome, major or clinically relevant nonmajor bleeding,were centrally evaluated by blinded investigators. Sinus recanalization on repeat brain imaging was a secondary outcome. Statistical analyses were exploratory. In total, 114 children with confirmed CVT were randomized. All children completed the follow-up. None of the 73 rivaroxaban recipients and 1 (2.4%; CVT) of the 41 standard anticoagulant recipients had symptomatic, recurrent VTE after 3 months (absolute difference, 2.4%; 95% confidence interval [CI], -2.6% to 13.5%). Clinically relevant bleeding occurred in 5 (6.8%; all nonmajor and noncerebral) rivaroxaban recipients and in 1 (2.5%; major [subdural] bleeding) standard anticoagulant recipient (absolute difference, 4.4%; 95% CI, -6.7% to 13.4%). Complete or partial sinus recanalization occurred in 18 (25%) and 39 (53%) rivaroxaban recipients and in 6 (15%) and 24 (59%) standard anticoagulant recipients, respectively. In summary, in this substudy of a randomized trial with a limited sample size, children with CVT treated with rivaroxaban or standard anticoagulation had a low risk of recurrent VTE and clinically relevant bleeding. This trial was registered at clinicaltrials.gov as #NCT02234843.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine
04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine > Neuropaediatrics

UniBE Contributor:

Grunt, Sebastian

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2473-9529

Publisher:

American Society of Hematology

Language:

English

Submitter:

Karen Lidzba

Date Deposited:

06 May 2021 16:44

Last Modified:

06 May 2021 16:53

Publisher DOI:

10.1182/bloodadvances.2020003244

PubMed ID:

33351120

BORIS DOI:

URI:

https://boris.unibe.ch/id/eprint/154418

Actions (login required)

Edit item Edit item
Provide Feedback